NIH’s Neuroscience Institute Plans to Limit Financial Support for Well-Funded Investigators

Under a new policy, the National Institute of Neurological Disorders and Stroke will provide fewer grants to labs receiving more than $1 million in funds.

Written byDiana Kwon
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

NCI, CHRIS SPIELMANN

The National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH), will limit the number of grants it provides to well-funded investigators, according to a new policy it announced last week (April 27).

In 2012, the NIH implemented an institutes-wide policy under which grant applications from investigators already receiving more than $1 million in funding would receive additional scrutiny. The new NINDS rules, which will apply to grants under consideration from January 2019 and beyond, will extend the stricter review to labs whose funding support would exceed $1 million after the acceptance of a pending proposal.

The policy “will allow us to fund more early stage investigators and help people who just missed the pay line [funding ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies